DUBAI, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - 31 Concept (31C), an emerging leader in network intelligence and cybersecurity innovation, today announced it will unveil its first patent-pending technology at ISS Asia 2025 in Singapore. The breakthrough, developed entirely within the company's 31 Concept Research Lab, marks a major milestone for the startup, which is stepping out of stealth mode after just seven months of intense development.31 Concept's Innovation PatentedThe 31 Concept Research Lab serves as the company's innovation engine, uniting world-class experts in deep packet inspection, AI-driven analytics, cybersecurity, and advanced networking. With decades of combined experience from projects spanning telecom, military, and national infrastructure, the lab's team operates at the intersection of applied research and practical deployment, delivering solutions designed to solve real-world challenges at scale."Our patent-pending technology is the direct result of the unique expertise and relentless drive inside our Research Lab," said Misha Hanin, CEO and Co-Founder of 31C. "We built this in record time without compromising on quality or innovation. This is just t...

香港，2025年8月11日 - (亚太商讯 via SeaPRwire.com) - 专注于微创介入冷冻治疗领域的创新医疗器械公司康沣生物科技（上海）股份有限公司（"康沣生物"或"公司"，股份代号：6922.HK）公布其截至2025年6月30日止六个月的中期业绩。报告期内，公司展现出强劲的增长动能与显著的经营优化，核心财务指标表现亮眼，特别是其呼吸介入产品线实现爆发式增长，标志着公司商业化进程步入快车道。呼吸介入产品成业绩增长核心引擎，全球领先优势凸显​​公告显示，2025年6月30日止六个月，康沣生物实现收入达人民币5,111万元，较2024年同期1,948万元激增162.4%，创下历史同期新高。这一增长主要源于公司在呼吸介入领域的战略性布局迎来收获期：公司2025年3月获国家药监局批准的恶性狭窄冷冻消融系统及此前上市的冷冻粘连治疗系统等呼吸介入产品销量迅猛增长，成为驱动收入增长的绝对主力；同时，公司与国际医疗巨头波士顿科学的中国附属公司波科国际医疗贸易（上海）有限公司("波科")在其他呼吸介入产品的中国大陆的经销合作也贡献了可观的增量收入。更值得一提的是，公司的哮喘冷冻消融系统获得美国食品及药物管理局授予的"突破性医疗器械"认证 ，成为中国企业在呼吸介入冷冻治疗领域首个获此国际权威认证的产品，为进军全球医疗市场奠定基础。康沣生物在呼吸介入领域构建了极具竞争力的产品矩阵，覆盖从恶性狭窄、良性狭窄、哮喘、慢阻肺（COPD）、肺周结节、慢性咳嗽到气道结核等多种重要适应症。其中：恶性狭窄冷冻消融系统已在中国成功商业化；哮喘、慢阻肺系统处于确证性临床试验阶段，预计2026年获批；咳嗽、结核、肺周结节等系统也处于不同研发阶段；冷冻粘连治疗系统含一次性冷冻探头及可重复使用冷冻探头已获批准并上市。这些产品的成功，主要建立在康沣两大核心技术平台之上--​独特的液氮冷冻消融技术（以液氮为冷媒能量源）和先进的柔性导管技术。该平台提供了深低温、精确控制、微创介入的能力，在治疗效率和安全性上具有显著优势，形成了竞争对手难以逾越的技术壁垒。​​​​平台价值裂变，多领域布局加速商业化康沣生物的核心价值不仅在于其亮眼的呼吸介入管线，更在于其作为创新型冷冻治疗平台企业的稀缺属性。公司以液氮冷冻技术和柔性导管技术为基石，成功将产品线拓展至多个庞大的治疗领域：其中，在血管介入领域：心脏冷冻消融系统（用于房颤治疗）已于2024年9月在中国商业化。Cryofocus冷冻消融系统（用于高血压治疗）获美国食品及药物管理局"突破性器械"认定，处于确证性临床阶段。肺动脉高压冷冻消融系统处于临床前研阶段。这些产品涉及的心血管适应症市场空间巨大。在经自然腔道内镜手术（NOTES）领域：呼吸介入领域如前所述，产品线丰富且领先。腫瘤介入领域如膀胱冷冻消融系统已在中国上市；胃部冷冻消融系统、食道冷冻喷雾治疗系统处...

香港，2025年8月11日 - (亚太商讯 via SeaPRwire.com) - 8月8日，全国首批数据中心REITs--南方润泽科技数据中心REIT与南方万国数据中心REIT正式登陆沪深交易所，上市首日双双涨停，分别报收5.850元和3.9元。两单产品的亮眼表现，不仅标志着REITs市场正式切入"科技新基建"赛道，也凸显了产业资本在推动算力基础设施证券化中的重要作用。作为两单项目的重要投资方，港股上市公司首程控股（0697.HK）再一次站在了市场关注的风口。通过全资子公司北京首源欣荣投资有限公司，以及旗下管理的北京平准基础设施不动产股权投资基金，首程控股分别投资了南方万国数据中心REIT与南方润泽科技数据中心REIT。这不仅是公司在数据中心领域的又一次精准布局，更是其深耕REITs市场战略版图的最新落子。一、切入"算力底座"，紧抓数字经济新机遇公开资料显示，南方万国数据中心REIT的底层资产为位于昆山花桥的国金数据云计算数据中心，机柜数4192个；南方润泽科技数据中心REIT的底层资产则为位于京津冀国家算力枢纽节点的润泽（廊坊）国际信息港A-18数据中心，机柜数5897个，上架率超99%。两大项目均属于区域核心算力资源，在支撑5G、人工智能、大数据等应用方面具有不可替代的战略价值。业内人士指出，数据中心REITs的推出，意味着公募REITs资产类型首次覆盖到科技创新基础设施领域，有助于推动算力资源高效配置，提升资本市场服务数字经济的能力。二、全链条布局，构建REITs生态闭环事实上，首程控股在REITs领域的布局早已形成全链条覆盖。从2021年作为首批公募REITs的最大战略投资者之一起，公司便围绕"Pre-REITs产业基金培育-平台运营管理-公募REITs退出-战略配售投资"建立了完整的生态体系。截至目前，首程控股REITs基金管理规模已突破300亿元，投资领域覆盖交通枢纽、城市更新、绿色能源、数据中心等多个板块。今年以来，公司相继投资了首农产业园REIT、华夏华电清洁能源REIT，并通过北京平准基金与国寿投资、财信人寿等机构合作，设立目标规模100亿元的平准基础设施基金，进一步夯实在REITs市场的产业资本地位。三、产业资本优势显现，助力市场良性发展作为产业资本，首程控股不仅提供资金，更依托自身在智能基础设施资产管理、运营、整合等方面的能力，为底层资产的运营效率和长期价值提升提供保障。这种"资金+运营"的双重赋能模式，使公司在REITs市场中形成了与单纯财务投资机构的差异化优势。分析人士认为，随着公募REITs市场规模的不断扩容，以及数据中心等新型基础设施的证券化步伐加快，首程控股有望在"科技新基建+REITs"这一新兴交汇赛道上持续受益，并巩固其在行业内的引领地位。Posted by All Way Success Company Limite...

HONG KONG, Aug 6, 2025 - (ACN Newswire via SeaPRwire.com) - 5 August, The well-known dual-listed beauty and skincare group in Asia, Natural Beauty Bio-Technology Limited ("Natural Beauty"), together with its subsidiaries (the "Group"; Hong Kong stock code: 00157), today announced its interim results for the six months ended 30 June 2025 (the "Review Period"). The Group's turnover and profit for the Review Period soared by nearly 70% to over HK$260 million and 136% to HK$11 million, respectively. A good number of its core indicators for the period also reached record highs, evidencing the strong development resilience and growth potential of the Group in the beauty and skincare sector.Mainland China, which is the core market of the Group, recorded turnover HK$220 million in the first half of 2025, up 101% year-on-year, and has thus become the main driving force of the Group’s overall performance growth. In terms of channels, the franchise model performed particularly well, contributing turnover of HK$200 million, a 115% increase year-on-year. In the Review Period, 237 new franchise stores were added, a leap of 88%. The rapidly expanding store network has given the segment solid supp...

HONG KONG, Aug 8, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels.With this label update, the previous requirement in accelerated approval stage to submit full confirmatory trial analysis to demonstrate clinical benefit has been formally removed. Additionally, data demonstrating NEFECON(R)’s efficacy in delaying kidney function decline has been included in the approved product label. IgAN is highly prevalent among Asian populations, with a 56% higher risk of progression to end-stage renal disease compared to other groups and often progresses more rapidly.Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON(R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This further demonstrates NEFECON(R)’s foundational first-line cornerstone treatment for IgAN pati...

RIYADH, KSA, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - Saudi Electricity Company (SEC) continued to deliver robust financial and operational performance in the second quarter and first half of 2025.Revenue for Q2 grew by 24% to reach SAR 27.7 billion, while gross profit rose by 42% to SAR 7.4 billion. Operating profit increased by 21% to SAR 6.8 billion, and net profit reached SAR 5.3 billion-marking a 22% year-on-year increase.For the first half of 2025, SEC reported a revenue growth of 23%, totalling SAR 47.2 billion. Gross profit rose by 40% to SAR 10.2 billion, operating profit increased by 20% to SAR 9.1 billion, and net profit grew by 19% to SAR 6.3 billion compared to the same period in 2024.This strong financial performance was primarily driven by higher allowed revenue due to the growth of the regulated asset base of the electricity network and increased electricity production revenues in response to rising energy demand. These gains were partially offset by higher operating and maintenance expenses due to network expansion, asset growth, and increased loads, as well as a rise in provisions for accounts receivable and a decrease in other income.SEC noted that the e...

KUALA LUMPUR, Aug 8, 2025 - (ACN Newswire via SeaPRwire.com) - Qube Integrated Malaysia Sdn. Bhd. (Qube), a leading local business events industry player celebrating its 20th anniversary this year, won 10 prestigious awards at the Malaysia Business Events Awards (MBEA) 2025, organised by the Malaysian Association of Convention and Exhibition Organisers and Suppliers (MACEOS) last night.The company, an established name in the MICE (Meetings, Incentives, Conferences and Exhibitions) industry, was honoured at the event held at the Kuala Lumpur Convention Centre with five Excellence Awards and five Merit Awards, out of the 10 categories it was shortlisted for, including:1. Exhibition Management Excellence Award: Qube for Malaysia International Halal Showcase (MIHAS) 20242. Trade Exhibition Excellence Award for events between 10,001–20,000 sqm: BuildXpo Malaysia 20243. Booth Design Excellence Award for booths below 72sqm held in overseas: MyCEB Pavilion at IMEX Frankfurt4. Booth Design Excellence Award for single deck booth 73 sqm & above: Proton Pavilion at KLIMS 20245. Stage Design Excellence Award: Acer APAC Predator League 20256. Trade Exhibition Excellence Merit Award (20,001 s...